Abstract
Background: Spinal Muscle Atrophy Type 1 (SMA1) is a hereditary neuromuscular disorder that affects the motor neuron, leading to sever muscles weakness and limited motor function. Zolgensma therapy has emerged as potential treatment option for SMA1, offering hope for improved outcomes and quality of life for affected infants. However, the effectiveness of the therapy in promoting physical development in SMA1 remains unclear1. This case study aim to explore the role of physiotherapy in improving the developmental milestones of an infant with SMA1 following gene therapy. Additionally, will utilize the Chop Intend assessment tool to assess and track the changes in infant’s motor function, strength, and over all physical development. Case discerption: 7 weeks new borne girl referred from neurology department to physical rehabilitation department, with history of SMA1. Management and outcomes: The baby was seen twice/week, assessed by CHOP-INTEND assessment tool and followed by active ROM exercises, stretching exercises and Neuro-developmental therapy for the last two years. Outcomes was measures by CHOPINTEND assessment, which improved from 45 to 64. Result: This study highlights the significant benefits of physiotherapy in improving motor milestones in patients with SMA1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
